

27 **Summary**

28 **Background**

29 The upsurge of pertussis post-COVID-19 and expansion of macrolide-resistant 30 *Bordetella pertussis* (MRBP) pose significant public health challenges worldwide. 31 China has experienced notable pertussis upsurge post-COVID-19, alongside an age 32 shift to older children, vaccine escape and a notable rise in MRBP prevalence. We 33 describe the genomic epidemiological investigation of these events.

34

35 **Method**

36 We did a retrospective, population-based study using culture-positive *B. pertussis* 37 from Children's Hospital of Fudan University (CHFU), the exclusive referral hospital 38 for childhood notifiable infectious diseases, in Shanghai, China between June 2016 39 and March 2024. We analysed strain and pertussis epidemiology dynamics by 40 integrating whole-genome sequencing of 723 strains with antimicrobial susceptibility, 41 transcriptomic proflie, and clinical data. We compared the genome sequences of 42 Shanghai strains with 6450 Chinese and global strains.

43

44 **Findings**

45 Coincident with national situtation, pertussis cases upsurged post-COVID-19 in 46 Shanghai. At CHFU, the number of confirmed cases (n=349) in the first three months 47 of 2024 exceeded the total case of previously years ($n \le 177$). Post-COVID-19, patients
48 shifted from predominantly infants (90%, 397/442) to widespread infection among shifted from predominantly infants (90%, 397/442) to widespread infection among 49 older children (infant: 16%, 132/844), with vaccinated individuals surging from 31% 50 (107/340) to 88% (664/756); MRBP prevalence increased from 60% (267/447) to 98% 51 (830/845). The emergence and expansion of a *ptxP3*-linage, macrolide-resistant novel 52 clone with MLVA type 28, MR-MT28, uniquely capable of causing substantial 53 infections among older children and vaccinated individuals, temporally strongly 54 associated with the pertussis upsurge and epidemiological transition. MR-MT28 55 exhibited increased expression of antigen genes including pertussis toxin genes, along 56 with high incidence of abnormal C-reactive protein, but associated with siginicantly 57 milder clinical symtoms (e.g. wheezing, facial blushing, *p*<0·01), higher proportion of 58 normal chest computed tomography $(p<0.05)$ and lower hospitalization rate $(p<0.01)$. 59 Phylogenomic clustering analysis revealed a higher proportion of MR-MT28 strains 60 grouping into clusters representing putative transmission. We reconstructed the 61 evolutionary history of MR-MT28, and showed that it most likely originated in China 62 around 2016 (95% highest probability density: 2013-2017) after acquring several 63 mutations, including a novel antigen allele *prn150* and 23S rRNA A2047G mutation. 64 Approximately one quarter (26%, 50/195) of MR-MT28 has evolved into predicted 65 PRN-deficient strains. MR-MT28 has been identified in four regions (Anhui, 66 Shanghai, Beijing and Guangdong) of China and continuously detected in Shanghai 67 and Beijing, suggesting domestic spread and colonization.

68

69 **Interpretation**

70 We identified a *ptxP3*-linage, macrolide-resistant novel clone, MR-MT28, and provide

71 evidence that pathogen evolution is more likely the primary factor driving pertussis 72 upsurge, age shift and vaccine escape. MR-MT28 potentially poses a high global 73 spread risk and warrants global surveillance. Macrolides may no longer be suitable as 74 first-line drugs for pertussis treatment in China.

75

76 **Funding**

77 National Key Research and Development Program of China (2021YFC2701800 and 78 2022YFC2304700), National Natural Science Foundation of China (82202567 and 79 32270003), Youth Innovation Promotion Association, Chinese Academy of Sciences 80 (2022278), Shanghai Rising-Star Program (23QA1410500), and Shanghai municipal 81 three-year action plan for strengthening the construction of the public health system 82 (2023-2025) GWVI-2.1.2.

83

84 **Key words:** pertussis, *Bordetella pertussis*, age shift, vaccine escape, 85 macrolide-resistant, MT28

86

87

88 **Research in context**

89 **Evidence before this study**

90 In the first two months of 2024, an unexpected upsurge in pertussis was seen in both 91 China and Europe. Furthermore, the pertussis upsurge in China exhibited atypical 92 patterns, including an age shift to older children, vaccine escape and a notable 93 increase in macrolide-resistant *Bordetella pertussis* (MRBP) prevalence. We aimed to 94 test the hypothesis linking pertussis upsurge and epidemiological transition to 95 pathogen evolution. We searched PubMed for molecular epidemiology studies of 96 macrolide-resistant *Bordetella pertussis* using the terms ("*Bordetella pertussis*" OR 97 "pertussis" OR "whooping cough") AND ("macrolide resistant" OR "erythromycin 98 resistant") for articles before March 2024 and identified 40 studies. MRBP has been 99 reported in eight counties, including United States, United Kingdom, France, Iran, 100 Cambodia, Vietnam, Japan and China. While MRBP incidence in other countries 101 remained low, it was notably high in China, accounting for 50% and even 90% of 102 strains across various regions. The risk of MRBP spreading out of China was 103 previously considered low, primarily because Chinese strains predominantly belonged 104 to *ptxP1*-lineage, whereas the globally prevalent lineage was *ptxP3*. However, the 105 situation is changing, as *ptxP3*-MRBP strains have been identified in multiple regions 106 of China since 2017. In Shanghai, we identified a sharply increase of *ptxP3*-MRBP 107 prevalence post-COVID-19, coinciding with pertussis age shift to older children and 108 vaccine escape. A similar scenario was independently observed in Beijing. 109 Additionanlly, there is a significant rise in pertussis cases since the beginning of 2024. 110 Currently, there is a lack of study testing the link between pertussis upsurge, 111 epidemiological transition, and the evolution of its causative pathogen.

112

113 **Added value of this study**

114 Our study identified a *ptxP3*-linage, macrolide-resistant novel clone, MR-MT28,

115 which is uniquely capable of causing substantial infections among older children and 116 vaccinated population, suggesting enhanced vaccine escape. The emergence and rapid 117 expansion of MR-MT28 temporally strongly associated with the upsurge of pertussis 118 cases, age shift, vaccine escape and notable rise in MRBP prevalence. MR-MT28 was 119 characterized by increased expression of antigen genes long with high incidence of 120 abnormal C-reactive protein, but associated with siginicantly milder clinical 121 sytmptoms, which may prolong the interval before seeking medical care, thereby 122 amplifying transmission opportunities. Phylogenomic clustering analysis indicated 123 that MR-MT28 may have increased transmissibility. Therefore, MR-MT28 may have 124 competitive advantages due to antimicrobial resistance, enhanced vaccine escape, 125 increased opportunities for transmission and transmissibility. We reconstructed the 126 evolutionary history of MR-MT28 and showed that it most likely originated in China 127 around 2016 after the acquisition of several mutations, and COVID-19 may have 128 promoted its expansion. Approximately one quarter of MR-MT28 strains has evolved 129 into predicted PRN-deficient strains. Our results showed the domestic spread and 130 colonization of MR-MT28.

131

132 **Implications of all the available evidence**

133 Our study provides evidence that pathogen evolution, rather than the widely accepted 134 notion of wanning immunity or 'immunity debt', is more likely the primary factor 135 driving pertussis upsurge, age shift and vaccine escape. MR-MT28 potentially poses a 136 high global spread risk, due to its consistent *ptxP3* allele and epidemiology across 137 many counties, together with resistance to first-line drugs and potentially competitive 138 advantages, which warrants global surveillance and research efforts. Macrolides may 139 no longer be suitable as first-line drugs for pertussis treatment in China.

- 140
- 141

142 **Introduction**

143 Pertussis (whooping cough) is a highly contagious disease primarily caused by 144 *Bordetella pertussis.* The introduction of the whole-cell vaccines (WCVs) in the 145 1950s, and the switch to acellular vaccines (ACVs) in the 1980–1990s, significantly 146 reduced pertussis disease burden.¹ However, the resurge of pertussis has been reported 147 globally during the past two decades.^{2–5} The burden of pertussis is still high, with an 148 estimated 24 million cases and 160,700 deaths in children younger than five years in 2014.⁶ In China, ACV was applied since 2007 and completely replaced WCV in 2012. 150 Despite over 99% vaccine coverage among children, the numbers of reported 151 pertussis cases sharply increased from <3,000 per year in 2006–2013 to 30,027 in 152 2019.⁷ A reduced incidence of pertussis has been reported in children since the 153 beginning of the COVID-19 pandemic, due to the non-pharmaceutical interventions.^{8,9} 154 However, the recent upsurge in pertussis post-COVID-19 restrictions have been 155 documented in China and Europe.^{10–14} In China, the number of pertussis cases 156 reported in the first two months of 2024 (32,380 cases) was >20 times higher than 157 during the same periods in previous years, approaching the total cases reported for the 158 entire year of 2023 (38,205 cases).^{10,11}

159

160 Pertussis resurge has been attributed to various factors, including wanning immunity, improved diagnostics, and *B. pertussis* evolution.^{2–5} The importance of *B. pertussis* 162 evolution is suggested by the antigenic divergence between circulating strains and 163 vaccine strains. Sequence divergence has been identified in several genes encoding 164 ACV antigens or their promotor, including filamentous hemagglutinin (Fha), pertactin 165 (Prn), fimbriae (Fim), pertussis toxin (Ptx) and its promoter $(ptxP)$.¹⁵ $ptxP3$ strains are 166 currently dominating infections in most of the high-income countries, probably due to 167 their higher virulence caused by more Ptx production.¹⁶ Moreover, Prn-deficient 168 strains which confer fitness advantages particular to ACV vaccinated populations, 169 have been increasingly reported and became dominant in multiple countries such as 170 Unite States and Australia.¹⁷ Besides *B. pertussis* evolution toward vaccine escape, the 171 emergence of macrolide-resistant *B. pertussis* (MRBP) mediated by A2047G mutation 172 in the 23s rRNA gene, which confers resistance to first-line drugs such as 173 erythromycin and azithromycin for pertussis treatment, posed further public health 174 issues. 18

175

176 The circulating *B. pertussis* stains and pertussis epidemiology in China differ 177 significantly from those in other countries. *ptxP1* strains have been predominant in 178 China until 2019,^{19–21} rather than globally prevalent $ptxP3$ strains. Moreover, the 179 incidence of MRBP in China is notably high, accounting for over 50% and even 90% 180 of strains in various regions, 2^{1-24} while MRBP remains rare in other countries. Since 181 Chinese MRBP strains were predominantly *ptxP1*, their risk of spreading out of China 182 was previously considered low. Additionally, pertussis patients in China were 183 primarily identified in infants less than one year old,²⁵ unlike the other countries 184 where resurgence of pertussis was more observed in older children and 185 adolescents/adults.^{4,5} However, the situation in China is changing, as $ptxP3-MRBP$

186 strains have been identified in multiple regions of China since 2017 ^{21–24} In Shanghai, 187 we previously reported that *ptxP3*-MRBP had replaced *ptxP1* strains and dominated 188 infections after 2020, with a substantially increased infections in older, vaccinated 189 children.^{22,23} Similar situation was recently identified in Beijing. During 2021-2022, 190 *ptxP3*-MRBP accounted for 78.8% patients, and the proportion of patients in children 191 over three years old doubled than before.²⁴ The $ptxP3$ -MRBP potentially poses a high 192 global spread risk because its consistent *ptxP3* allele and epidemiology across many 193 counties.

194

195 Coincident with national situtation, pertussis cases upsurged post-COVID-19 in 196 Shanghai. We have carried out continuous surveillance of *B. pertussis* stains and 197 pertussis in Shanghai since 2016, and obtained strains and corresponding clinical data 198 covering the transition period pre- and post-COVID-19. We previously described the 199 genotype dynamics of *ptxP3*-MRBP based on a subset of strains by multi-locus 200 variable-number tandem-repeat analysis $(MLVA)^{22,23}$ Compared with traditional 201 typing methods such as MLVA, whole-genome sequencing (WGS) provides finer 202 resolution and more comprehensive information including virulence and antimicrobial 203 genes. In this study, we took advantages of WGS and sequenced culture-positive *B.* 204 *pertussis* stains between June 2016 and March 2024. By combining with phenotypic, 205 transcriptomic, and clinical data, we aim to investigate the link between pertussis 206 upsurge, epidemiological transition, and *B. pertussis* evolution. We further compared 207 Shanghai strains with Chinese and global strains to investigate its domestic and global 208 spread risk.

209

210 **Methods**

211 **Isolates sampling and participants**

212 Pertussis is a notifiable disease in China. We did a retrospective, population-based 213 study in Shanghai, the most populous city in China, and enrolled pertussis patients 214 from Children's Hospital of Fudan University (CHFU), the exclusive referral hospital 215 for childhood notifiable infectious diseases. The nasopharyngeal swab samples of 216 patients with suspected pertussis infection are collected and delivered to microbiology 217 laboratory. Pertussis patients were defined as positive culture and/or PCR testing, or 218 showed typical clinical symptoms of pertussis. We studied culture-positive *B.* 219 *pertussis* between June 2016 and March 2024 (all the culture-positive strains beween 220 June 2016 and August 2023, and randomly selected strains between September 2023 221 and March 2024, appendix p 2). The laboratory testing results and clinical data were 222 extracted from medical records and all data analysis was anonymous. For comparison, 223 we also included the genomes of 11 randomly selected strains (appendix p 12) 224 collected after 2019 in Beijing (n=8, from Capital Institute of Pediatrics, 2019-2022) 225 and Shenzhen, Guangdong (n=3, from Shenzhen Center for Disease Control and 226 Prevention, 2023). The study protocol was approved by the Ethics Committee of the 227 CHFU (No. 2022-66).

228

229 **Whole-genome sequencing and analysis**

230 Genomic DNA of *B. pertussis* strains were extracted using QIAamp DNA mini kit 231 (QIAGEN) and whole-genome sequencing were performed on Illumina NovaSeq 232 platform. Sequencing data were strictly trimmed and analyzed as previously 233 described.²⁶ Briefly, species identification based on sequencing data were performed 234 using Kraken 2. Core-genome single-nucleotide-polymorphisms (SNPs) were 235 identified using the Snippy pipeline. Maximum-likelihood phylogenetic trees were 236 constructed using RAxML-NG based on core-genome SNPs. Genome assembly was 237 preformed using shovill pipeline. Assembled sequences were used for vaccine antigen 238 typing by searching against BIGSdb-Pasteur genomic platform for *Bordetella*.²⁷ Dated 239 phylogeny and population size dynamics were analyzed using BEAST 1.10 with 240 Skygrid coalescent model. We performed pangenome-level analysis to identified 241 lineage/clone-specific genomic variations, including SNPs, gene presence/absence 242 and unitigs using unitig-caller and pyseer. A total of 6439 publicly available genome 243 from 34 countries and six continents were downloaded from NCBI GenBank or SRA 244 database, with accession numbers listed in the appendix (appendix p 13).

245

246 **MLVA and antimicrobial susceptibility testing**

247 Multiple locus variable-number tandem repeat analysis (MLVA) was performed as 248 described by Schouls et al.²⁸ The minimum inhibitory concentrations (MICs) of four 249 antimicrobial agents were determined by the E-test. The standardized interpretation 250 criteria are based on our previous report. 22

251

252 **Transcriptomic analysis and quantification of antigen gene expression**

253 The RNA of *B. pertussis* strains was extracted using QIANGEN RNA extraction kit 254 (TIANGEN BIOTECH, Beijing, China). cDNA library construction and sequencing 255 were performed on Illumina NovaSeq platform at Novogene Co. Ltd. (Beijing, China). 256 Differentially expressed genes identification and pathway enrichment analysis were 257 performed using R packages DESeq2 and ClusterProfiler. Transcriptomic and 258 genomic sequencing data have been deposited in the NCBI Sequence Read Archive 259 (SRA) under accession number PRJNA1071282.

260

261 To quantify antigen gene expression level, reverse transcription was conducted using 262 YEASEN cDNA Synthesis SuperMix for qPCR kit (Yeasen Biotechnology, Shanghai, 263 China). Amplifications of virulence genes were performed using the Applied 264 Biosystems QuantStudioTM 5 Real-Time qPCR system (ThermoFisher SCIENTIFIC, 265 Waltham, MA, US), with initial denaturation for 5 min at 94 \degree C, and 35 cycles at 266 94 °C for 30 s, annealing for 30 s at 52 °C, followed by elongation at 72 °C for 30 s, 267 and a final step at 72 \degree C for 5 min. The presence of gene specific amplicons was 268 verified visually by 2% agarose gel electrophoresis using Glodview staining. *B.* 269 *pertussis* ATCC9797 was used as the reference strain and the house-keeping gene *tyrB* 270 was used as the reference gene. The virulence gene expressions were calculated by the 271 comparative CT method $(2^{-\Delta\Delta CT})$.

272

273 **Statistical analysis**

274 Datasets were compared with Chi-squared tests for categorical data and 275 Mann-Whitney test for continuous data using GraphPad Prism 9. *P*-values less than 276 0.05 were considered statistically significant.

277

278 **Role of the funding source**

279 The funding sources for this study had no role in the study design, data collection, 280 data analysis, data interpretation, or writing of the manuscript. The corresponding 281 author had full access to all the data in the study and has final responsibility for the 282 decision to submit this manuscript for publication.

283

284 **Results**

285 Coincident with national situtation, pertussis cases upsurged post-COVID-19 in 286 Shanghai (appendix p 1). From June 2016 to March 2024, a total of 2659 patients 287 were diagnosed with pertussis in CHFU. Among these, 1479 (56%) patients were 288 confirmed by positive strain cultures, while the others were diagnosed by positive 289 PCR-detection or showed typical pertussis symptoms. We enrolled all the 290 culture-positive *B. pertussis* strains beween June 2016 and August 2023 (n= 714), and 291 100 randomly selected strains (13% culture-positive strains) between September 2023 292 and March 2024. A total of 712 (87%) enrolled culture-positive strains were 293 successfully sequenced and identified as *B. pertussis*. The remaining were identified 294 as other *Bordetella* (n=4) or no longer viable (n=98). Of the 712 patients, 678 (95%) 295 were children patients and the remaining were households. Among children patients 296 with available clinical and vaccination data (table 1), 68% (458/672) were infants 297 (aged ≤1y), 46% (310/674) were female, and 52% (284/546) had been vaccinated. A total of 507 (71%) sequenced strains were MRBP, which are resistant to ervthromycin. 298 total of 507 (71%) sequenced strains were MRBP, which are resistant to erythromycin, 299 azithromycin and clarithromycin, but all were susceptible to 300 sulfamethoxazole/trimethoprim. All MRBP strains carried the 23S rRNA A2047G 301 mutation.

302

303 Two phases of pertussis epidemic were identified in Shanghai, with the emergence of 304 COVID-19 as transition point (figure 1). From pre- (n=447) to post-COVID-19 305 (n=845), the proportion of MRBP infections in children increased from 60% to 98%. 306 Moreover, patients shifted from being dominant by infants (90%, 397/442) to 307 widespread infection among older children (infant: 16%, 132/844), with a notable 308 increase in the proportion of vaccinated population, surging from 31% (107/340) to 88% 309 (664/756).

310

311 To characterize the circulating *B. pertussis* lineages, we constructed a phylogenic tree 312 of 712 Shanghai strains based on core-genome SNPs (figure 2A). Two lineages were 313 identified, which were designated as *ptxP1-* and *ptxP3*-lineage based on *ptxP* alleles. 314 Nearly all (98%, 313/321) *ptxP1-*lineage strains and 50% (194/391) *ptxP3-*lineage 315 strains were MRBP.

316

317 Within *ptxP3-*lineage, all MRBP strains and one MSBP strain clustered together and

318 belonged to a specific clone with MLVA type 28 (MT28), which was designed as 319 MR-MT28. A novel antigen allele *prn150*, with one synonymous mutation (C531T) 320 compared with *prn2*, was identified in MR-MT28. The *prn* of 26% (50/195) 321 MR-MT28 strains were predicted to be PRN-deficient. The genotypes of MR-MT28 322 were *ptxP3/prn150* or PRN-deficient */fhaB1/ptxC2/ptxA1/firm2-1/fim3-1*. Except 323 MR-MT28, all other MT28 strains were MSBP and designated as MS-MT28, which is 324 closely related to MR-MT28 on the phylogenic tree (figure 2A). Non-MT28 strains of 325 *ptxP3-*lineage was designated as *ptxP3-*other.

326

327 The emergence and expansion of MR-MT28 temporally strongly correlated with the 328 transition of pertussis epidemiology and upsurge of cases (table 1 and figure 2B). 329 Post-COVID-19, MR-MT28 proportion increased sharply and dominated infections 330 since 2022. The proportion of *prn150* or PRN-deficient strains kept increasing 331 alongside the expansion of MR-MT28. Notably, MR-MT28 uniquely caused 332 widespread infection among older children (infant: 25%, 47/189) and accounted for a 333 substantial proportion (87%, 150/172) of infections among vaccinated population. In 334 contrast, other types predominantly infected infants $(\geq 83\%)$, with a much lower proportion of infections among vaccinated population $(\leq 39\%)$. proportion of infections among vaccinated population $(\leq 39\%)$.

336

337 Increased transmission may contribute to the expansion of MR-MT28. To investigate 338 this possibility, genomic clustering analysis based on SNP-distance was performed to 339 infer putative transmissions. Strains from patient-household pairs were most likely 340 from recent transmission. There was no SNP between strains from 30 (90%) of 33 341 patient-household pairs, which were consistent with recent transmission, while the 342 remaining three pairs had 32 or more SNPs. We therefore selected zero SNP 343 difference as the cutoff to infer genomic cluster representing putative transmission. 51% 344 (96/190) MR-MT28 strains were assigned into genomic clusters, which was higher 345 than other types and significantly $(p<0.01)$ higher than $ptxPI$ and $ptxP3$ -other (figure 346 2C), indicating a potentially increased transmissibility of MR-MT28.

347

348 We randomly selected eight strains (MR-MT28: n=3, MS-MT28: n=3, *ptxP3*-other: 349 n=2) for transcriptomic sequencing to investigate the possible molecular mechanism 350 of MR-MT28 expansion. We found substantial differences of transcriptomic profiles 351 between MT-28 (MR-MT28 and MS-MT28) and *ptxP3*-other strains (figure 3A), with 352 879 differentially expressed genes (DEGs) identified (appendix p 163). Enrichment 353 analysis of DEGs indicated that virulence-related pathways including bacterial 354 secretion system (ko03070) and pertussis (ko05133) were significantly (*p*<0·01) 355 up-regulated (fold change >2) and bacterial motility proteins pathway was 356 significantly downregulated (fold change <-2) in MT-28 strains. More specifically, 357 most antigen genes were significantly upregulated, including Ptx encoding genes 358 (*ptxA* to *ptxE*). There was limited difference of transcriptomic profiles between 359 MR-MT28 and MS-MT28, with only eight DEGs not associated with known 360 virulence or antigen genes identified (figure 3B).

361

362 To validate gene expression results, we further quantified the expression of *ptxA* and 363 *prn* of 40 strains (ten randomly selected strains per type) by quantitative PCR (qPCR, 364 figure 3C). Consistent with transcriptomic analysis, the expression levels of *ptxA* in 365 MT28 strains were significantly $(p<0.01)$ higher than $ptxP3$ -other strains and higher 366 than $ptxPI$ -lineage strains ($p=0.06$). There is no significant difference in the 367 expression of *ptxA* and *prn* between MR-MT28 and MS-MT28 under the growth 368 conditions tested, despite MR-MT28 carrying a novel *prn* allele.

369

370 In line with increased expression of Ptx encoding genes, the incidence of abnormal 371 C-reactive protein (CRP) associated with MR-MT28 (20%) was significantly higher 372 than *ptxP1*-lineage (8%) and *ptxP3*-other (9%), and higher than MS-MT28 (5%, 373 *p*=0·089). However, overall, MR-MT28 infection caused milder clinical symptoms 374 (table 1), including spasmodic cough, wheezing, sputum production, facial blushing 375 and post-tussive vomiting, which were significantly $(p<0.01$ or 0.05) milder for 376 MR-MT28 than other types. Moreover, MR-MT28 infections exhibited a significantly 377 (*p*<0·05) higher proportion of normal chest computed tomography results and a 378 significantly (*p*<0·01) lower hospitalization rate. Clinical symptoms among patients 379 with same age catogory or vaccination status showed showed similar trends (appendix 380 p1).

381

382 To investigate the origin and spread of MR-MT28 in China and globe, we newly 383 sequenced 11 Beijing and Guangdong strains between 2019 and 2023, and compared 384 with 6439 global strains. Phylogenetic analysis showed that MT28 clone existed in 385 multiple regions worldwide, but so far, MR-MT28 was exclusively identified in China 386 (figure 4A, B).

387

388 The MT28 clone was not a recently emerged one and likely originated from Europe 389 around 2003 (95% highest probability density [HPD]: 1999-2006, figure 3B). It has 390 spread in Europe and United States and was inferred to introduce to China around 391 2007 (95% HPD: 2005-2011). There are only two SNPs between MR-MT28 and 392 MS-MT28 strains: 23S rRNA A2047G mutation and *BP0685* (dehydrogenase/oxidase) 393 G15951A synonymous mutation. The *prn150* was not only identified in MR-MT28, 394 but also found in a MS-MT28 strain closely related to MR-MT28 (figure 2A, 4B). 395 After the acquisition of *prn150*, *BP0685* G15951A mutation and 23S rRNA A2047G 396 mutation, MR-MT28 most likely originated in China in 2016 (95% HPD: 2013-2017), 397 one year prior to the first report of MR-MT28 strain in Anhui, China in 2017 .²¹ 398 Notably, a sub-clone of MR-MT28 evolved into predicted PRN-deficient around 2019 399 (95% HPD: 2017-2019). Now MR-MT28 has been identified in four regions of China, 400 including Anhui, Shanghai, Beijing and Guangdong (figure 4B). Beyond Shanghai, 401 continuously identification of MR-MT28 occurred in Beijing during 2019-2022, 402 indicating that domestic spread and colonization has occurred.

403

404 The effective population size of MT28 clone has steadily increase since its 405 introduction into China (figure 4C). Intriguingly, following the origination of 406 MR-MT28 in 2016, the overall population size did not increase but instead declined 407 until the advent of COVID-19. Post-COVID-19, MR-MT28 population size increased 408 rapidly, indicating that COVID-19 might be a critical factor for its rapid expansion.

409

410 **Discussion**

411 The continuous surveillance and sampling in Shanghai provide a valuable opportunity 412 to comprehensively investigate the link between pertussis upsurge, epidemiological 413 transition, and *B. pertussis* evolution. Though the integration of large-scale WGS with 414 phenotypic, transcriptomic, and clinical data, we identified and characterized a novel 415 *ptxP3*-linage, macrolide-resistant clone, MR-MT28, which accounted for a substantial 416 proportion of infections in older children and vaccinated individuals. The emergence 417 and rapid expansion of MR-MT28 temporally strongly associated with pertussis 418 upsurge, age shift, vaccine escape and sharp increase in MRBP prevalence.

419

420 While previous reports have noted pertussis age shift to older children and adolescents 421 and vaccine escape, 4.5 the situation in Shanghai exhibits distinct features. First, unlike 422 gradual shifts observed in most countries, the shift in Shanghai occurred very quickly. 423 Within two years, the proportion of older children $(>1y)$ and vaccinated individuals 424 surged from 10% and 31% to 84% and 88%, respectively, with the emergence of 425 COVID-19 as the transition point. Second, pertussis shift in other countries was 426 generally associated with the expansion of more virulent *ptxP3* strains, resulting in 427 more severe clinical symptoms and higher hospitalization rates¹⁶. However, although 428 MR-MT28 exhibited increased *ptxA* expression levels and higher incidence of 429 abnormal CRP, it has been associated with generally milder clinical symptoms and a 430 low hospitalization rate. Third, whereas the circulating *ptxP3*-lineage in most 431 countries was polyphyletic with multiple subtypes and no dominant clone reported, a 432 single clone, MR-MT28, dominated infections in Shanghai post-COVID-19 and has 433 spread to multiple regions of China.

434

435 The causes of pertussis upsurge, age shift and vaccine escape have been attributed to 436 multiple factors, including wanning immunity, 'immunity debt', ⁹ improved 437 diagnostics and pathogen evolution, with the first two being considered as the primary 438 factors. $2-5$ While wanning immunity or 'immunity debt' could explain the increased 439 incidence among older children and upsurge of cases, it should not affect *B. pertussis* 440 population composition and dynamics, and cannot explain the observation of 441 MR-MT28 replacing other lineages and dominating infections. Improved diagnostics 442 similarly do not affect *B. pertussis* population dynamics, and our results are based 443 cultured strains, which are independent of diagnostic methods. Moreover, independent 444 observations in Beijing²⁴ provide further evidence that this scenario is not a bias 445 caused by diagnostics.

446

447 We proposed that pathogen evolution is more likely the primary factor driving the 448 scenario in Shanghai and China. MR-MT28 is uniquely capable of causing a 449 substantial proportion of infections among older children and vaccinated individuals,

450 suggesting enhanced vaccine escape. Moreover, the relatively milder clinical 451 symptoms may prolong the interval before seeking medical care, thereby amplifying 452 transmission opportunities. Phylogenomic clustering analysis provided evidence for 453 the increased transmissibility of MR-MT28. Consequently, MR-MT28 may have 454 competitive advantages due to antimicrobial resistance, enhanced vaccine escape, 455 increased opportunities for transmission and transmissibility. In addition, the effective 456 population size of MR-MT28 increased rapidly post-COVID-19, which could be 457 related to the increased family contacts, particularly with unvaccinated infants, the 458 major source for pertussis transmission, 2^9 due to long-term lockdown and home life. 459 These factors combined may have promoted the rapid expansion and dominance of 460 MR-MT28.

461

462 While the molecular mechanism underlying *B. pertussis* vaccine escape remains 463 unclear, three antigen genes have been implicated in this phenomenon: 464 autotransporters genes *brkA* and *vag8*, and surface protein filamentous hemagglutinin 465 gene *fhaB*.^{30–33} Intriguingly, all three genes were up-regulated in MR-MT28 compared 466 with *ptxP3*-other strains. This, together with upreguation of Ptx encoding genes and 467 other unidentified factors, may contribute to its enhanced vaccine escape. Despite the 468 capacity to infect vaccinated individuals, clinical symptoms of MR-MT28 infection 469 appear to be mild. This suggests that while the vaccine may not entirely prevent 470 infection, it can attenuate clinical symptoms, a phenomenon also observed in other 471 pathogens such as $SARS-CoV-2.³⁴$

472

473 By integrating public data and 11 newly sequenced genomes from Beijing and 474 Guangdong strains collected after 2019, our results showed the domestic spread and 475 colonization of MR-MT28. Newly sequenced strains were randomly selected, and no 476 information including subtyping and antimicrobial resistance was known in advance. 477 Notably, a surprisingly high proportion of these strains (Beijing: 5/8, Guangdong: 2/3) 478 were MR-MT28, suggesting that MR-MT28 may have cryptically dominated 479 infections in these regions, like in Shanghai, but had not been identified due to limited 480 surveillance and analysis or associated with their milder clinical symptoms. In 481 addition to the expansion in China, MR-MT28 potentially has a high global spread 482 risk because its consistent *ptxP3* allele and epidemiology across many counties. Given 483 its resistance to first-line drugs and potentially competitive advantages, MR-MT28 484 warrants comprehensively global surveillance and research efforts.

485

486 Extremely high prevalence of MRBP indicates that macrolides are no longer suitable 487 as first-line drugs for pertussis treatment in Shanghai and even China. 488 Sulfamethoxazole/trimethoprim could be a good replacement because all MRBP 489 strains were susceptible to it. While traditional drug susceptibility testing replies on 490 strain culture and is time-consuming, PCR testing targeting specific mutations such as 491 23S rRNA A2047G mutation carried by all MRBP strains, offers a supplement or 492 alternative. For MR-MT28, *BP0685* G15951A mutation or *prn150* are candidate 493 targets, though the latter may present some problems (one non-MR-MT28 strains

494 carried *prn150*, 26% MR-MT28 were predicted PRN-deficient).

495

496 Our studies have several limitations. First, most samples used for strain culture were 497 obtained after patients had received antimicrobial treatment, which may introduce bias 498 to the incidence of MRBP. However, this issue is common and remained consistent 499 throughout the sampling period. Second, due to the unavailability of Ptx antibodies in 500 China, we could only investigate the expression levels. Nonetheless, high expression 501 does not necessarily correspond to increased Ptx production and virulence. Finally, 502 while we provided evidence of domestic spread and colonization of MR-MT28, due to 503 the small sample size except Shanghai, the incidence of MR-MT28 in China requires 504 further evaluation based on more samples, especially samples collected 505 post-COVID-19.

506

507 In conclusion, a novel *B. pertussis ptxP3*-linage clone, MR-MT28, has emerged and 508 dominated infections in Shanghai post-COVID-19. MR-MT28 may have competitive 509 advantages due to antimicrobial resistance, enhanced vaccine escape, increased 510 opportunities for transmission and transmissibility, which drove the pertussis upsurge, 511 age shift, vaccine escape and sharp increase in MRBP prevalence. We reconstructed 512 the evolutionary history of MR-MT28 and demonstrated its domestic spread and 513 colonization. This novel clone potentially has a higher global spread risk because its 514 consistent *ptxP3* allele and epidemiology across many counties, which warrants 515 further comprehensive global surveillance and research efforts. Macrolides may no 516 longer be suitable as first-line drugs for pertussis treatment in China due to the 517 extremely high prevalence of MRBP post-COVID-19.

518

519 **Contributors**

520 CW, PF, CY, and LG contributed to the conception of this project. PF and GY were 521 responsible for collection of clinical and laboratory data. WC and PF performed 522 clinical and laboratory data analysis. CY and LX performed bioinformatics analysis of 523 whole genome sequence data. JQ, JZ and YL participated the genome preparision and 524 qPCR. JQ, YK, SQ, SW, JZ and YL participated in the experiments. CY and PF 525 prepared the manuscript. All authors contributed to the interpretation of results and 526 critical review of the manuscript.

527

528 **Declaration of interests**

- 529 We declare no competing interests.
- 530

531 **Acknowledgments**

532 This work was supported by grants from the National Key Research and Development 533 Program of China (2021YFC2701800 and 2022YFC2304700), National Natural 534 Science Foundation of China (82202567 and 32270003), Youth Innovation Promotion 535 Association, Chinese Academy of Sciences (2022278), and Shanghai Rising-Star 536 Program (23QA1410500), and Shanghai municipal three-year action plan for 537 strengthening the construction of the public health system (2023-2025) GWVI-2.1.2.

	Total	ptxPI	MR-MT28	MS-MT28	$ptxP3$ -other	p-value (MR-MT28 vs others)
Age						
$0-1y$	458 (68%)	247 (83%)	47 (25%)	21 (100%)	143 (87%)	All pairs $p<0.01$
$>1-3v$	48 (7%)	20(7%)	16(8%)	$\sqrt{2}$	12(7%)	
$4-6y$	77 (11%)	17(6%)	56 (30%)		4(2%)	All pairs $p<0.01$
$7-10v$	80 (12%)	13 (4%)	61 (32%)		6(4%)	All pairs $p<0.01$
>10v	9(1%)		9(5%)			
Gender						
Female	310 (46%)	136 (45%)	87 (46%)	8 (38%)	79 (48%)	
Male	365 (54%)	163 (55%)	103 (54%)	13 (62%)	86 (52%)	
Vaccination						
Yes	284 (52%)	89 (39%)	150 (87%)	3(21%)	42 (33%)	All pairs $p<0.01$
No	262 (48%)	142 (61%)	22(13%)	11(79%)	87 (67%)	All pairs $p<0.01$
Clinical characteristics						
Spasmodic cough	593 (87%)	283 (94%)	136 (72%)	20 (95%)	154 (93%)	All pairs $p<0.05$
Paroxysmal cough	565 (83%)	252 (83%)	159 (84%)	19 (90%)	135 (82%)	
Cockcrow-like cough	123 (18%)	60(20%)	29 (15%)	3(14%)	31 (19%)	
Wheeze	147 (22%)	81 (27%)	14 (7%)	11(52%)	41 (25%)	All pairs $p<0.01$
Sputum	446 (66%)	199 (66%)	108 (57%)	20 (95%)	119 (72%)	All pairs $p<0.05$
Facial blushing	273 (40%)	135 (45%)	33 (17%)	12 (57%)	93 (56%)	All pairs $p<0.01$
Post-tussive vomiting	202 (30%)	101 (33%)	32 (17%)	8 (38%)	61 (37%)	All pairs $p<0.05$
Runny nose	251 (37%)	116 (38%)	63 (33%)	10(48%)	62 (38%)	
Fever history	72 (11%)	38 (13%)	18 (9%)	3(14%)	13 (8%)	
Apnea	$4(1\%)$	$2(1\%)$	$1(1\%)$	$0(0\%)$	$1(1\%)$	
Hospitalization	138 (20%)	81 (27%)	12(6%)	8 (38%)	37(22%)	All pairs $p<0.01$
Hospitalization days	$6(5-10)$	$6(5-10)$	$4(1-7)$	$6(5-10)$	$7(5-10)$	ptxPI: p<0.01 <i>ptxP3</i> -other: $p<0.05$
Chest computed tomography (CT)						
Normal	159 (23%)	64 (21%)	59 (31%)	$2(10\%)$	34 (21%)	All pairs $p<0.05$
Moderate (bronchitis)	294 (43%)	119 (39%)	90 (47%)	7(33%)	78 (47%)	
Severe						
(bronchopneumonia or	225 (33%)	119 (39%)	41 (22%)	12 (57%)	53 (32%)	All pairs $p<0.05$
pneumonia)						
Laboratory testing						
Abnormal CRP	78 (12%)	25(8%)	37 (20%)	1(5%)	15 (9%)	ptxPI: p<0.01 $ptxP3$ -other: $p<0.01$
Abnormal WBC	380 (58%)	177 (61%)	86 (47%)	15 (71%)	102(64%)	All pairs $p<0.05$

626 **Table 1. Demographic, clinical and laboratory characteristics of children patients.**

627 Data are n (%) or median (IQR). CRP: C-reactive protein, WBC: white blood cell

628

629

630 **Figure legends**

631 **Figure 1. Pertussis epidemic dynamics in Shanghai, China between 2016 and** 632 **2024.** (A) Monthly number of culture-positive children patients and annually 633 proportions of MRBP/*ptxP3*/*ptxP3*-MRBP infection, older children (aged >1y) and 634 vaccinated populations. Data from 2020 was not analysed due to insufficient sample 635 size (n=1). (B) Transition of pertussis epidemiology from pre- to post-COVID-19 636 stage.

637

638 **Figure 2. Phylogenomic and epidemiological characteristics of MR-MT28.** (A) 639 Phylogenetic tree, source and antigen gene alleles of Shanghai strains. (B) Temporal 640 dynamics and age and vaccination composition of patients of different lineages/clones. 641 (C) Proportion of genomically clustered strains.

642

643 **Figure 3. Transcriptomic (RNA-seq) and qPCR analyses of gene expression.** (A,B) 644 Volcano plot showing differentially expressed genes (left) and pathways (right). (C) 645 Expression levels of seven antigen genes detected by qPCR. **: *p*<0·01, NS: not

- 646 significant.
- 647

648 **Figure 4. MR-MT28 in China and global context.** (A) Phylogenic tree of Shanghai 649 and global strains. The colors of outer ring indicated geographical regions. MR-MT28 650 and MS-MT28 were highlighted with red and orange backgrounds. (B) Maximum 651 clade credibility tree of MT28 clone and geographical distribution of MR-MT28 in 652 China. Branch colors indicated geographical regions. Key time points and genetic 653 events were indicated by arrows and triangles. (C) Effective population size dynamics 654 of MT28 clone inferred by Bayesian Skygrid analysis.

